FP187

DRUG3 trials

Sponsors

Forward-Pharma GmbH, Skane University Hospital

Conditions

Plaque PsoriasisPsoriatic Arthritis

Phase 2

Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis

CompletedNCT01230138

Forward-Pharma GmbHPlaque Psoriasis

Start: 2010-09-30End: 2012-05-31Updated: 2012-12-11

Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic Arthritis

WithdrawnNCT02475304

Skane University HospitalPsoriatic Arthritis

Start: 2015-05-31End: 2017-06-30Updated: 2017-10-05

Phase 3

Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis

WithdrawnNCT01815723

Forward-Pharma GmbHPlaque Psoriasis

Start: 2016-06-30End: 2017-06-30Updated: 2016-08-09